Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial
8.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-09-30 07:42
摘要：
Tolododekin alfa, an IL-12 anchored drug conjugate, was evaluated in a Phase 1 trial involving patients with advanced solid tumors. The study demonstrated safety, with no dose-limiting toxicities, and a preliminary efficacy rate of 60% stable disease. The drug's design allows for local retention and immune activation within the tumor microenvironment, suggesting a promising approach for enhancing cancer immunotherapy. Further clinical development is warranted based on these findings.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
Tolododekin alfa shows safety and tolerability with no dose-limiting toxicities.
60% of patients achieved stable disease, indicating preliminary efficacy.
The study supports the continued clinical development of tolododekin alfa.
真实性检查
否
AI评分总结
Tolododekin alfa, an IL-12 anchored drug conjugate, was evaluated in a Phase 1 trial involving patients with advanced solid tumors. The study demonstrated safety, with no dose-limiting toxicities, and a preliminary efficacy rate of 60% stable disease. The drug's design allows for local retention and immune activation within the tumor microenvironment, suggesting a promising approach for enhancing cancer immunotherapy. Further clinical development is warranted based on these findings.